The DOI matches its Crossref record.
Adjuvant systemic therapy for male breast carcinoma
Abstract
BACKGROUND: In the current study, the authors describe the M. D. Anderson experience with adjuvant systemic therapy in male breast carcinoma patients. METHODS: A total of 156 men with a diagnosis of breast carcinoma registered and were treated at the M. D. Anderson Cancer Center between 1944 and 2001. One hundred thirty‐five men had nonmetastatic breast carcinoma at diagnosis and were included in this analysis. Patients' charts were retrospectively reviewed to obtain details of patient characteristics, adjuvant therapy, and outcomes. Analysis was performed with descriptive statistics; the log rank test was used to compare outcomes. RESULTS: The median patient age was 59 years (range, 25–80 yrs). Median follow‐up was 13.8 years (range, 0.6–32.5 yrs). Sixty percent of patients had tumors 2 cm or smaller. Pathologic lymph node involvement was seen in 55% of patients. Tumors were estrogen receptor‐positive in 85% of cases and progesterone receptor‐positive in 71%. Chemotherapy was administered to 32 men (84% with adjuvant chemotherapy, 6% with neoadjuvant chemotherapy, and 9% with both). Approximately 81% received anthracycline‐based regimens; 9% received additional taxanes; and 16% were treated with cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF). The median number of cycles was 6 (range, 4–14 cycles). Thirty‐eight men received adjuvant hormonal therapy (92% received tamoxifen and 8% were treated with other therapy). The 5‐year and 10‐year overall survival rates were 86% and 75%, respectively, for men with lymph node‐negative disease and 70% and 43%, respectively, for men with lymph node‐positive disease. For men with lymph node‐positive disease, adjuvant chemotherapy was associated with a lower risk of death (hazards ratio [HR] of 0.78), although this difference was not statistically significant. Overall survival was significantly better for men who received adjuvant hormonal therapy (HR of 0.45; P = 0.01). CONCLUSIONS: This relatively large series of men with breast carcinoma suggests that men benefit from adjuvant systemic therapy for breast carcinoma, with the greatest benefit from adjuvant hormonal therapy. Cancer 2005. © 2005 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., Giordano, S. H., Hudis, C. A., Malin, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3756 · Cited by 796
Self-citationFentiman, I. S., Fourquet, A., & Hortobagyi, G. N. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68226-3 · Cited by 744
Self-citationBiganzoli, L., Wildiers, H., Oakman, C., Marotti, L., Loibl, S., Kunkler, I., Reed, M., Ciatto, S., Voogd, A. C., Brain, E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70383-7 · Cited by 567
Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer
Anderson, W. F., Jatoi, I., Tse, J., & Rosenberg, P. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8162 · Cited by 495
Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations
Korde, L. A., Zujewski, J. A., Kamin, L., Giordano, S., Domchek, S., Anderson, W. F., Bartlett, J. M. S., Gelmon, K., Nahleh, Z., Bergh, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5729 · Cited by 487
Self-citation
Metadata
- Authors
- Giordano, S. H., Perkins, G. H., Broglio, K., Garcia, S. G., Middleton, L. P., Buzdar, A. U., & Hortobagyi, G. N.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2005-11-03
- Volume
- 104
- Issue
- 11
- Pages
- 2359-2364
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1968447609
- Cited by
- 200
- References
- 0
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjuvant systemic therapy for male breast carcinoma. https://app.cochat.ai/papers/10.1002/cncr.21526
- The paper
- Giordano, S. H., Perkins, G. H., Broglio, K., Garcia, S. G., Middleton, L. P., Buzdar, A. U., & Hortobagyi, G. N. (2005). Adjuvant systemic therapy for male breast carcinoma. Cancer. https://doi.org/10.1002/cncr.21526
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.